OA-09 Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma
Marta Larrayoz, Chad Chad Bjorklund, Maddalen Jimenez, Teresa Lozano, Sonia Sanz, Elena Arriazu, Rebecca Zon, Juan Roberto Rodríguez-Madoz, Bruno Paiva, Paula Rodríguez-Otero, Jesús San-Miguel, Felipe Prósper, Juan Jose Lasarte, Benjamin Ebert, Patrick Hagner, Jose Angel Martinez-Climent
{"title":"OA-09 Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma","authors":"Marta Larrayoz, Chad Chad Bjorklund, Maddalen Jimenez, Teresa Lozano, Sonia Sanz, Elena Arriazu, Rebecca Zon, Juan Roberto Rodríguez-Madoz, Bruno Paiva, Paula Rodríguez-Otero, Jesús San-Miguel, Felipe Prósper, Juan Jose Lasarte, Benjamin Ebert, Patrick Hagner, Jose Angel Martinez-Climent","doi":"10.1016/S2152-2650(24)01850-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S6-S7"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024018500","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍：
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
